Dr. Agarwal's Health Care Limited (NSE:AGARWALEYE)
India · Delayed Price · Currency is INR 517.05
+2.45 (0.48%)
Nov 9, 2026, 10:48 AM IST
Dr. Agarwal's Health Care Revenue
Dr. Agarwal's Health Care had revenue of 6.65B INR in the quarter ending September 30, 2026, with 33.39% growth. This brings the company's total for the last twelve months to 23.58B, up 25.64% year-over-year. In the fiscal year ending March 31, 2026, Dr. Agarwal's Health Care had annual revenue of 20.80B with 21.57% growth. That makes Dr. Agarwal's Health Care the 15,816th largest company in the world by revenue and 839th in India.
Revenue (ttm)
23.58B
Revenue Growth
+25.64%
P/S Ratio
6.94
Revenue / Employee
n/a
Employees
n/a
Market Cap
163.92B
Revenue by Geography
- India 18.71B 89.9%
- outside India 2.09B 10.1%
Fiscal year ended Mar 31, 2026 See the full Dr. Agarwal's Health Care breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 20.80B | 3.69B | 21.57% |
| Mar 31, 2025 | 17.11B | 3.79B | 28.44% |
| Mar 31, 2024 | 13.32B | 3.14B | 30.86% |
| Mar 31, 2023 | 10.18B | 3.22B | 46.25% |
| Mar 31, 2022 | 6.96B | 2.25B | 47.73% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 616.31B |
| Divi's Laboratories | 112.30B |
| Lenskart Solutions | 103.83B |
| Laurus Labs | 78.23B |
| Syngene International | 35.22B |
| NATCO Pharma | 34.85B |
| Eris Lifesciences | 33.12B |
| Pfizer | 26.54B |